Immunitor's article on affordable AIDS drugs

Immunitor publishes articles on AIDS drugs affordable Immunitor Corporation โ € "Biotech-Thai company announces the publication of โ € ~ low against the cost of HIV compounds: potential application in AIDS treatment in developing countries in Current Pharmaceutical Design ((18 Vol 9): pp. 1419-1431, 2003). The abstract of the paper can be found at the National Library of Medicine PubMed (http://www.ncbi.nlm.nih.gov / entrez / query.fcgi? cmd = Retrieve & db = PubMed & list_uids = 12769722 & dopt = Abstract). The essential elements of this document was filed last year in IAEN symposium โ € ~ Economy of HIV / AIDS in developing countries, held during the 14th International AIDS Conference in Barcelona in July 2002 (www.iaen.org/files.cgi/7014_Bourinbaiar.pdf). IAEN or Business Network International AIDS is a multinational NGO that focuses on affordable HIV / AIDS and treatment, providing data and analysis tools for scientists and policymakers working to define and implement the policy of cost-effective AIDS. It has advanced considerably in recent years in developing HIV drugs. However, the current cost of AIDS drugs is the main obstacle preventing their use in developing countries, where 98% of patients with HIV reside. The annual average price of AIDS treatment and care of patients with partners in the industrialized countries is as high as $ 22,000 € โ "an amount that corresponds to the total income of not less than one hundred people in developing countries. Even in these countries, uninsured patients can not afford expensive treatment. From the outset it was clear that the most viable and cost to achieve this goal is to identify HIV drugs among already available and preferably on OTC medicines, which have historically been used for clinical purposes, independent. Immunitor document summarizing their original research in the discovery and development of affordable and potentially promising AIDS drugs. Nonsteroidal anti-HIV and immunomodulatory drugs such as warfarin, cimetidine, levamisole, acetaminophen, gramicidin, and V-1 Immunitor (an AIDS vaccine by mouth, also known as V1) are described and discussed in relation to clinical application . President Immunitor, Vichai Jirathitikal pharmacologist, noted that ~ โ € โ € ฆ publication of this landmark document marks the 2nd anniversary of public release of V1 in Thailand. The deployment was the first Mass June 2, 2001 in Thailand and Japan at the stadium in Bangkok. On this historic day, we have V1 to 4,000 people. During summer and autumn of 2001 we have the ex-rate of 40,000 AIDS patients. Today, over 65,000 patients in over 60 countries including 26 African countries have benefited from our ceaseless effort. We were and still face resistance to our work. It's hard being a pioneer in the highly competitive, especially if you are from third world countries. However, despite the difficulties and lack of public funds, we could publish our clinical experience in international journals and several pairs of this publication is further evidence that a small company like ours can make a difference in the global AIDS crisis . 'For more information and reprints, please write to: info@immunitor.com